Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285711 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2 study of Lupus Membranous Nephropathy, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 7
- Study locations
NCT03285711: Completed Phase 2 study of Lupus Membranous Nephropathy, sponsored by Gilead Sciences.
NCT03285711 is a Phase 2 study of Lupus Membranous Nephropathy that has completed, run by Gilead Sciences. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03285711, a Phase 2 study of Lupus Membranous Nephropathy, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
Primary Outcome
Urine protein was assessed by urinary protein excretion during a 24-hour urine collection.
Conditions Studied
Interventions
- DRUG Filgotinib
- DRUG Lanraplenib
- DRUG Lanraplenib placebo
- DRUG Filgotinib placebo
Study Locations (7)
Georgia
- Emory University School of Medicine - Atlanta
- Georgia Nephrology Research Institute - Lawrenceville
Alabama
- University of Alabama at Birmingham (UAB) - Birmingham
California
- Stanford University - Palo Alto
Florida
- University of Florida - Gainesville
Michigan
- University of Michigan - Ann Arbor
North Carolina
- University of North Carolina at Chapel Hill / UNC School of Medicine - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2020-02-03 |
| Phase | Phase 2 |
What the finished NCT03285711 record still lists
NCT03285711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Lupus Membranous Nephropathy appearing as the primary indexed condition, and to 4 interventions - of which Filgotinib is the first listed.
NCT03285711 lists 7 locations in 6 states (Georgia, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT03285711 about?
NCT03285711 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)". The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
What is the current status of trial NCT03285711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-10-06. Estimated completion is 2020-02-03.
What conditions does trial NCT03285711 study?
This clinical trial studies the following conditions: Lupus Membranous Nephropathy.
What interventions are being tested in trial NCT03285711?
The interventions under investigation include: Filgotinib (DRUG), Lanraplenib (DRUG), Lanraplenib placebo (DRUG), Filgotinib placebo (DRUG).
Who is sponsoring clinical trial NCT03285711?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03285711 being conducted?
This trial has 7 study locations across Alabama, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03285711's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI